Frankfurt - Delayed Quote EUR

BioLineRx Ltd. (YP2A.F)

Compare
0.0745
+0.0235
+(46.08%)
At close: January 29 at 8:10:46 AM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
21,991.0000
4,800.0000
--
--
--
Cost of Revenue
6,866.0000
3,692.0000
--
--
--
Gross Profit
15,125.0000
1,108.0000
--
--
--
Operating Expense
42,971.0000
44,100.0000
29,157.0000
24,777.0000
22,927.0000
Operating Income
-27,846.0000
-42,992.0000
-29,157.0000
-24,777.0000
-22,927.0000
Net Non Operating Interest Income Expense
-1,455.0000
-162.0000
-1,118.0000
-729.0000
-1,256.0000
Other Income Expense
9,382.0000
-17,461.0000
5,324.0000
-1,548.0000
-5,838.0000
Pretax Income
-19,919.0000
-60,615.0000
-24,951.0000
-27,054.0000
-30,021.0000
Net Income Common Stockholders
-19,918.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Diluted NI Available to Com Stockholders
-19,918.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Basic EPS
-0.30
-0.90
-0.45
-0.60
-1.80
Diluted EPS
-0.30
-0.90
-0.45
-0.60
-1.80
Basic Average Shares
76,046.0740
64,224.3680
51,597.1320
44,195.5800
16,856.2930
Diluted Average Shares
76,046.0740
64,224.3680
51,597.1320
44,195.5800
16,856.2930
Total Operating Income as Reported
-34,548.0000
-49,694.0000
-29,157.0000
-24,777.0000
-22,927.0000
Total Expenses
49,837.0000
47,792.0000
29,157.0000
24,777.0000
22,927.0000
Net Income from Continuing & Discontinued Operation
-19,918.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Normalized Income
-2,222.0000
-42,918.0000
-31,030.0000
-25,400.0000
-24,742.0000
Interest Income
2,252.0000
2,007.0000
694.0000
277.0000
236.0000
Interest Expense
3,682.0000
2,144.0000
1,786.0000
984.0000
1,470.0000
Net Interest Income
-1,455.0000
-162.0000
-1,118.0000
-729.0000
-1,256.0000
EBIT
-16,237.0000
-58,471.0000
-23,165.0000
-26,070.0000
-28,551.0000
EBITDA
-13,318.0000
-57,087.0000
-22,511.0000
-25,367.0000
-27,617.0000
Reconciled Cost of Revenue
6,866.0000
2,659.0000
--
--
--
Reconciled Depreciation
2,919.0000
1,384.0000
654.0000
703.0000
934.0000
Net Income from Continuing Operation Net Minority Interest
-19,918.0000
-60,614.0000
-24,951.0000
-27,054.0000
-30,021.0000
Total Unusual Items Excluding Goodwill
-17,696.0000
-17,696.0000
6,079.0000
-1,654.0000
-5,279.0000
Total Unusual Items
-17,696.0000
-17,696.0000
6,079.0000
-1,654.0000
-5,279.0000
Normalized EBITDA
4,378.0000
-39,391.0000
-28,590.0000
-23,713.0000
-22,338.0000
12/31/2020 - 4/13/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2UV.DU Applied Therapeutics Inc
0.5630
-2.00%
 
M55.F MacroGenics, Inc.
2.8800
-0.48%
 
3G0.BE Altimmune Inc
6.43
-4.20%
 
0M4.DU Mersana Therapeutics Inc
0.5988
+1.39%
 
2UV.F Applied Therapeutics, Inc.
0.5710
+10.87%
 
1VT.DU Viking Therapeutics Inc
32.32
+0.53%
 
AT20.F Atara Biotherapeutics, Inc.
8.30
+11.41%
 
8AW0.BE Ocean Biomedical Inc
0.1930
+6.63%
 
NV4.F Cellectar Biosciences, Inc.
0.2160
+8.00%
 
8AW0.F Ocean Biomedical, Inc.
0.1940
-11.82%